| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hematopoietic Stem Cells | 17 | 2018 | 268 | 2.440 |
Why?
|
| Fibroblasts | 11 | 2017 | 902 | 1.620 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 11 | 2016 | 245 | 1.260 |
Why?
|
| Discoidin Domain Receptor 2 | 2 | 2019 | 2 | 1.260 |
Why?
|
| Fracture Healing | 2 | 2018 | 29 | 1.050 |
Why?
|
| Cell Lineage | 7 | 2015 | 146 | 0.810 |
Why?
|
| Osteoblasts | 3 | 2018 | 99 | 0.780 |
Why?
|
| CD4-Positive T-Lymphocytes | 3 | 2019 | 226 | 0.750 |
Why?
|
| Osteocalcin | 2 | 2018 | 37 | 0.750 |
Why?
|
| Fractures, Bone | 2 | 2019 | 132 | 0.740 |
Why?
|
| Blood Vessels | 4 | 2004 | 102 | 0.720 |
Why?
|
| Drug Design | 1 | 2020 | 107 | 0.710 |
Why?
|
| Leukocyte Common Antigens | 2 | 2019 | 41 | 0.700 |
Why?
|
| Animals | 43 | 2022 | 20881 | 0.690 |
Why?
|
| Tumor Microenvironment | 3 | 2016 | 213 | 0.670 |
Why?
|
| Antigens, CD34 | 2 | 2018 | 75 | 0.670 |
Why?
|
| Hip Fractures | 1 | 2019 | 26 | 0.650 |
Why?
|
| Peptide Fragments | 2 | 2020 | 483 | 0.650 |
Why?
|
| Mice, Inbred C57BL | 17 | 2019 | 2791 | 0.650 |
Why?
|
| Diet, High-Fat | 1 | 2019 | 81 | 0.640 |
Why?
|
| Antiviral Agents | 1 | 2020 | 211 | 0.640 |
Why?
|
| General Surgery | 1 | 2019 | 95 | 0.620 |
Why?
|
| Osteoporosis | 1 | 2019 | 88 | 0.620 |
Why?
|
| Mice | 30 | 2021 | 8474 | 0.620 |
Why?
|
| Cell Differentiation | 10 | 2018 | 1034 | 0.610 |
Why?
|
| Adipose Tissue | 1 | 2019 | 221 | 0.600 |
Why?
|
| Teaching | 1 | 2019 | 169 | 0.590 |
Why?
|
| Learning | 1 | 2019 | 186 | 0.580 |
Why?
|
| Wound Healing | 4 | 2019 | 260 | 0.550 |
Why?
|
| Disease Models, Animal | 8 | 2019 | 2550 | 0.550 |
Why?
|
| Osteogenesis | 4 | 2019 | 152 | 0.520 |
Why?
|
| Pulmonary Fibrosis | 1 | 2017 | 157 | 0.520 |
Why?
|
| Neovascularization, Physiologic | 4 | 2018 | 164 | 0.510 |
Why?
|
| Neoplasms, Experimental | 1 | 2015 | 118 | 0.490 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2013 | 756 | 0.470 |
Why?
|
| Clinical Competence | 1 | 2019 | 657 | 0.460 |
Why?
|
| Neovascularization, Pathologic | 1 | 2015 | 183 | 0.460 |
Why?
|
| Chondrocytes | 2 | 2015 | 27 | 0.450 |
Why?
|
| Osteocytes | 1 | 2012 | 8 | 0.420 |
Why?
|
| Tibial Fractures | 1 | 2012 | 25 | 0.420 |
Why?
|
| Mice, Transgenic | 8 | 2018 | 1033 | 0.410 |
Why?
|
| Neoplastic Stem Cells | 1 | 2012 | 84 | 0.400 |
Why?
|
| Tibia | 1 | 2012 | 93 | 0.400 |
Why?
|
| Veterans | 1 | 2019 | 904 | 0.390 |
Why?
|
| Collagen | 3 | 2019 | 636 | 0.380 |
Why?
|
| Carcinoma | 1 | 2012 | 215 | 0.380 |
Why?
|
| Bone Morphogenetic Protein 2 | 3 | 2019 | 57 | 0.360 |
Why?
|
| Osteogenesis Imperfecta | 1 | 2010 | 8 | 0.360 |
Why?
|
| HIV-1 | 2 | 2022 | 177 | 0.350 |
Why?
|
| Chemokine CCL2 | 1 | 2010 | 101 | 0.340 |
Why?
|
| Flow Cytometry | 5 | 2019 | 489 | 0.340 |
Why?
|
| Green Fluorescent Proteins | 6 | 2018 | 200 | 0.320 |
Why?
|
| Skull | 2 | 2018 | 63 | 0.320 |
Why?
|
| Endothelium, Vascular | 4 | 2004 | 371 | 0.300 |
Why?
|
| Cell Line, Tumor | 7 | 2015 | 1851 | 0.280 |
Why?
|
| Bone Marrow Cells | 1 | 2007 | 217 | 0.270 |
Why?
|
| Cells, Cultured | 8 | 2019 | 2673 | 0.260 |
Why?
|
| Stem Cells | 1 | 2007 | 248 | 0.260 |
Why?
|
| MicroRNAs | 4 | 2016 | 447 | 0.260 |
Why?
|
| Bone Marrow | 2 | 2018 | 168 | 0.250 |
Why?
|
| Proto-Oncogene Proteins c-pim-1 | 2 | 2015 | 87 | 0.230 |
Why?
|
| Virus Replication | 2 | 2022 | 104 | 0.230 |
Why?
|
| Neoplasms | 3 | 2015 | 1667 | 0.230 |
Why?
|
| Blood Cells | 1 | 2003 | 27 | 0.230 |
Why?
|
| Vitamin A | 1 | 2004 | 111 | 0.230 |
Why?
|
| Biomarkers | 4 | 2019 | 1593 | 0.220 |
Why?
|
| Epithelial-Mesenchymal Transition | 2 | 2015 | 135 | 0.220 |
Why?
|
| Humans | 26 | 2022 | 68618 | 0.210 |
Why?
|
| Inflammation | 2 | 2019 | 1030 | 0.200 |
Why?
|
| Spumavirus | 1 | 2021 | 1 | 0.200 |
Why?
|
| Integrases | 1 | 2021 | 31 | 0.200 |
Why?
|
| Simian Acquired Immunodeficiency Syndrome | 1 | 2022 | 29 | 0.200 |
Why?
|
| Simian Immunodeficiency Virus | 1 | 2022 | 28 | 0.200 |
Why?
|
| Transcription Factors | 3 | 2021 | 753 | 0.200 |
Why?
|
| Protein Multimerization | 1 | 2021 | 71 | 0.190 |
Why?
|
| Protein Kinases | 1 | 2021 | 122 | 0.190 |
Why?
|
| Female | 17 | 2019 | 38074 | 0.190 |
Why?
|
| Immunohistochemistry | 4 | 2019 | 1174 | 0.190 |
Why?
|
| Male | 17 | 2019 | 37321 | 0.190 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2020 | 20 | 0.190 |
Why?
|
| Tissue Scaffolds | 2 | 2019 | 111 | 0.190 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2018 | 507 | 0.190 |
Why?
|
| Cell Movement | 5 | 2014 | 630 | 0.180 |
Why?
|
| Molecular Docking Simulation | 1 | 2020 | 78 | 0.180 |
Why?
|
| Vesicular Transport Proteins | 1 | 2021 | 87 | 0.180 |
Why?
|
| Coturnix | 3 | 2004 | 22 | 0.170 |
Why?
|
| Nuclear Proteins | 1 | 2021 | 271 | 0.170 |
Why?
|
| HEK293 Cells | 1 | 2020 | 326 | 0.170 |
Why?
|
| Protein Conformation | 1 | 2020 | 362 | 0.170 |
Why?
|
| X-Ray Microtomography | 3 | 2018 | 50 | 0.170 |
Why?
|
| DNA | 1 | 2021 | 597 | 0.160 |
Why?
|
| Mandible | 1 | 2019 | 53 | 0.160 |
Why?
|
| Comparative Effectiveness Research | 1 | 2019 | 36 | 0.160 |
Why?
|
| Organogenesis | 1 | 2019 | 49 | 0.160 |
Why?
|
| Benzylamines | 1 | 2018 | 28 | 0.160 |
Why?
|
| Nanofibers | 1 | 2018 | 21 | 0.160 |
Why?
|
| Heterocyclic Compounds | 1 | 2018 | 24 | 0.160 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2018 | 266 | 0.160 |
Why?
|
| Mucin-1 | 1 | 2018 | 35 | 0.160 |
Why?
|
| Dental Pulp | 1 | 2018 | 10 | 0.160 |
Why?
|
| Sertraline | 1 | 2018 | 62 | 0.160 |
Why?
|
| Periodontal Ligament | 1 | 2018 | 16 | 0.160 |
Why?
|
| Histone Deacetylase 1 | 1 | 2018 | 32 | 0.150 |
Why?
|
| Th1 Cells | 1 | 2018 | 101 | 0.150 |
Why?
|
| Research | 1 | 2019 | 214 | 0.150 |
Why?
|
| Logistic Models | 2 | 2019 | 1420 | 0.150 |
Why?
|
| Macrophages | 2 | 2018 | 647 | 0.150 |
Why?
|
| Transplantation, Homologous | 3 | 2009 | 242 | 0.150 |
Why?
|
| Th17 Cells | 1 | 2018 | 116 | 0.150 |
Why?
|
| Osteonectin | 1 | 2018 | 69 | 0.150 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2015 | 710 | 0.140 |
Why?
|
| Neoplasm Invasiveness | 3 | 2014 | 369 | 0.140 |
Why?
|
| Silicon Dioxide | 1 | 2017 | 61 | 0.140 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2017 | 77 | 0.140 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2018 | 116 | 0.140 |
Why?
|
| Vaccination | 1 | 2018 | 189 | 0.140 |
Why?
|
| Colony-Forming Units Assay | 2 | 2007 | 78 | 0.140 |
Why?
|
| Vestibulocochlear Nerve Diseases | 1 | 2016 | 10 | 0.140 |
Why?
|
| Ouabain | 1 | 2016 | 32 | 0.140 |
Why?
|
| Hematopoiesis | 2 | 2015 | 108 | 0.140 |
Why?
|
| Phenotype | 2 | 2017 | 947 | 0.140 |
Why?
|
| Antigens, CD | 1 | 2017 | 230 | 0.140 |
Why?
|
| Gene Expression Regulation, Developmental | 3 | 2018 | 328 | 0.140 |
Why?
|
| RNA, Messenger | 6 | 2018 | 1664 | 0.130 |
Why?
|
| Nicotine | 1 | 2019 | 350 | 0.130 |
Why?
|
| Cochlear Nerve | 1 | 2016 | 83 | 0.130 |
Why?
|
| Whole-Body Irradiation | 2 | 2006 | 52 | 0.130 |
Why?
|
| Umbilical Veins | 1 | 2015 | 54 | 0.130 |
Why?
|
| Breast Neoplasms | 2 | 2016 | 1536 | 0.120 |
Why?
|
| Metformin | 1 | 2015 | 63 | 0.120 |
Why?
|
| Catalase | 1 | 2015 | 85 | 0.120 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2015 | 282 | 0.120 |
Why?
|
| Disease Progression | 3 | 2013 | 1038 | 0.120 |
Why?
|
| Hypoglycemic Agents | 2 | 2015 | 362 | 0.120 |
Why?
|
| Eukaryotic Initiation Factors | 1 | 2014 | 11 | 0.120 |
Why?
|
| Somites | 2 | 2004 | 6 | 0.120 |
Why?
|
| Esophageal Neoplasms | 1 | 2015 | 150 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2014 | 33 | 0.120 |
Why?
|
| Embryo, Nonmammalian | 2 | 2004 | 64 | 0.110 |
Why?
|
| HIV Infections | 1 | 2022 | 791 | 0.110 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2014 | 63 | 0.110 |
Why?
|
| Collagen Type I | 4 | 2009 | 175 | 0.110 |
Why?
|
| Adipocytes | 2 | 2015 | 88 | 0.110 |
Why?
|
| Allantois | 2 | 2003 | 3 | 0.110 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2015 | 332 | 0.110 |
Why?
|
| Embryo, Mammalian | 2 | 2004 | 176 | 0.110 |
Why?
|
| Microscopy, Confocal | 2 | 2004 | 337 | 0.110 |
Why?
|
| Health Status Disparities | 1 | 2016 | 326 | 0.110 |
Why?
|
| Peroxiredoxins | 1 | 2013 | 34 | 0.110 |
Why?
|
| Blotting, Western | 1 | 2015 | 954 | 0.110 |
Why?
|
| Core Binding Factor Alpha 1 Subunit | 1 | 2012 | 16 | 0.110 |
Why?
|
| Chondrogenesis | 1 | 2012 | 15 | 0.110 |
Why?
|
| Antioxidants | 1 | 2015 | 304 | 0.110 |
Why?
|
| Proto-Oncogene Protein c-ets-1 | 1 | 2013 | 65 | 0.110 |
Why?
|
| Myocardial Infarction | 1 | 2018 | 807 | 0.110 |
Why?
|
| Pluripotent Stem Cells | 1 | 2013 | 42 | 0.110 |
Why?
|
| Lung | 1 | 2017 | 849 | 0.100 |
Why?
|
| Signal Transduction | 6 | 2018 | 2689 | 0.100 |
Why?
|
| Adenocarcinoma | 1 | 2015 | 475 | 0.100 |
Why?
|
| Fibronectins | 2 | 2010 | 130 | 0.100 |
Why?
|
| Cell Communication | 1 | 2012 | 116 | 0.100 |
Why?
|
| Apoptosis | 2 | 2018 | 1641 | 0.100 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2015 | 468 | 0.100 |
Why?
|
| Myocardium | 1 | 2018 | 1204 | 0.100 |
Why?
|
| Risk Factors | 2 | 2019 | 5731 | 0.100 |
Why?
|
| Cell Proliferation | 4 | 2019 | 1174 | 0.100 |
Why?
|
| Amino Acid Motifs | 2 | 2021 | 77 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-ets | 1 | 2011 | 79 | 0.090 |
Why?
|
| Mice, Congenic | 1 | 2010 | 13 | 0.090 |
Why?
|
| Spiral Ganglion | 1 | 2010 | 47 | 0.090 |
Why?
|
| Hematologic Diseases | 1 | 2010 | 20 | 0.090 |
Why?
|
| Connective Tissue | 1 | 2010 | 61 | 0.090 |
Why?
|
| Myelin Sheath | 1 | 2010 | 115 | 0.090 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2015 | 629 | 0.090 |
Why?
|
| Gene Expression | 1 | 2012 | 770 | 0.090 |
Why?
|
| Neoplasm Transplantation | 1 | 2010 | 160 | 0.090 |
Why?
|
| Binding Sites | 2 | 2021 | 631 | 0.090 |
Why?
|
| Thrombocytopenia | 1 | 2010 | 122 | 0.090 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2011 | 282 | 0.090 |
Why?
|
| Proto-Oncogene Protein c-fli-1 | 1 | 2010 | 106 | 0.090 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 1 | 2010 | 63 | 0.080 |
Why?
|
| Clone Cells | 2 | 2006 | 67 | 0.080 |
Why?
|
| Retrospective Studies | 2 | 2019 | 7277 | 0.080 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2009 | 124 | 0.080 |
Why?
|
| Biomarkers, Tumor | 1 | 2012 | 508 | 0.080 |
Why?
|
| Actins | 2 | 2009 | 249 | 0.080 |
Why?
|
| Young Adult | 1 | 2019 | 5717 | 0.070 |
Why?
|
| Thrombopoiesis | 1 | 2006 | 4 | 0.070 |
Why?
|
| United States | 1 | 2019 | 7367 | 0.070 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2018 | 209 | 0.070 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2006 | 29 | 0.070 |
Why?
|
| Stem Cell Transplantation | 1 | 2006 | 58 | 0.070 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2015 | 1085 | 0.070 |
Why?
|
| Aged | 2 | 2019 | 14862 | 0.070 |
Why?
|
| Models, Biological | 1 | 2010 | 981 | 0.070 |
Why?
|
| Cell Nucleus | 2 | 2021 | 305 | 0.060 |
Why?
|
| Mesoderm | 2 | 2003 | 231 | 0.060 |
Why?
|
| Time Factors | 2 | 2004 | 4655 | 0.060 |
Why?
|
| Stromal Cells | 1 | 2006 | 113 | 0.060 |
Why?
|
| Protein Binding | 2 | 2021 | 1027 | 0.060 |
Why?
|
| Prostatic Neoplasms | 1 | 2011 | 778 | 0.060 |
Why?
|
| Cellular Senescence | 1 | 2005 | 112 | 0.060 |
Why?
|
| Neurons | 1 | 2010 | 881 | 0.060 |
Why?
|
| Heart Valves | 1 | 2006 | 171 | 0.060 |
Why?
|
| Low Density Lipoprotein Receptor-Related Protein-2 | 1 | 2004 | 5 | 0.060 |
Why?
|
| Tumor Cells, Cultured | 1 | 2006 | 852 | 0.060 |
Why?
|
| Tretinoin | 1 | 2004 | 92 | 0.060 |
Why?
|
| Virion | 1 | 2003 | 31 | 0.060 |
Why?
|
| Cardiovascular System | 1 | 2004 | 85 | 0.060 |
Why?
|
| Cell Size | 1 | 2003 | 76 | 0.060 |
Why?
|
| Recombination, Genetic | 1 | 2003 | 62 | 0.060 |
Why?
|
| Middle Aged | 2 | 2019 | 21147 | 0.060 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2015 | 304 | 0.060 |
Why?
|
| Adult | 2 | 2019 | 21403 | 0.060 |
Why?
|
| Organ Culture Techniques | 1 | 2003 | 122 | 0.050 |
Why?
|
| Cell Count | 1 | 2003 | 248 | 0.050 |
Why?
|
| RNA, Small Interfering | 2 | 2015 | 434 | 0.050 |
Why?
|
| Morphogenesis | 1 | 2003 | 159 | 0.050 |
Why?
|
| Endothelial Growth Factors | 1 | 2002 | 25 | 0.050 |
Why?
|
| Lymphokines | 1 | 2002 | 49 | 0.050 |
Why?
|
| Receptors, Cell Surface | 1 | 2004 | 248 | 0.050 |
Why?
|
| Chickens | 1 | 2003 | 232 | 0.050 |
Why?
|
| Fetal Blood | 2 | 2016 | 131 | 0.050 |
Why?
|
| Esterification | 1 | 2021 | 25 | 0.050 |
Why?
|
| HeLa Cells | 2 | 2014 | 237 | 0.050 |
Why?
|
| Oligonucleotides | 1 | 2021 | 34 | 0.050 |
Why?
|
| TATA-Binding Protein Associated Factors | 1 | 2021 | 1 | 0.050 |
Why?
|
| Transcription Factor TFIID | 1 | 2021 | 4 | 0.050 |
Why?
|
| Manganese | 1 | 2021 | 26 | 0.050 |
Why?
|
| RNA Polymerase II | 1 | 2021 | 14 | 0.050 |
Why?
|
| Chlorides | 1 | 2021 | 68 | 0.050 |
Why?
|
| Macaca mulatta | 1 | 2022 | 77 | 0.050 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2002 | 146 | 0.050 |
Why?
|
| Protein Structure, Quaternary | 1 | 2021 | 31 | 0.050 |
Why?
|
| Protein Domains | 1 | 2021 | 74 | 0.050 |
Why?
|
| Transfection | 2 | 2015 | 782 | 0.050 |
Why?
|
| Acetates | 1 | 2021 | 74 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2014 | 331 | 0.050 |
Why?
|
| Lentiviruses, Primate | 1 | 2021 | 2 | 0.050 |
Why?
|
| Nuclear Pore | 1 | 2021 | 2 | 0.050 |
Why?
|
| Reverse Transcription | 1 | 2021 | 3 | 0.050 |
Why?
|
| Virus Integration | 1 | 2021 | 5 | 0.050 |
Why?
|
| Capsid | 1 | 2021 | 8 | 0.050 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2003 | 411 | 0.050 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2021 | 55 | 0.050 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2004 | 689 | 0.050 |
Why?
|
| Cell Adhesion Molecules | 1 | 2022 | 199 | 0.050 |
Why?
|
| Viral Proteins | 1 | 2021 | 150 | 0.050 |
Why?
|
| Host-Pathogen Interactions | 1 | 2021 | 69 | 0.050 |
Why?
|
| Cytoplasm | 1 | 2021 | 155 | 0.050 |
Why?
|
| Structure-Activity Relationship | 1 | 2021 | 420 | 0.040 |
Why?
|
| Pregnancy | 2 | 2019 | 2334 | 0.040 |
Why?
|
| DNA-Binding Proteins | 1 | 2003 | 700 | 0.040 |
Why?
|
| Molar | 1 | 2019 | 27 | 0.040 |
Why?
|
| Absorbable Implants | 1 | 2019 | 29 | 0.040 |
Why?
|
| Maternal Exposure | 1 | 2019 | 75 | 0.040 |
Why?
|
| B7-2 Antigen | 1 | 2018 | 23 | 0.040 |
Why?
|
| Immunity, Cellular | 1 | 2018 | 80 | 0.040 |
Why?
|
| Cancer Vaccines | 1 | 2018 | 61 | 0.040 |
Why?
|
| CD11b Antigen | 1 | 2018 | 47 | 0.040 |
Why?
|
| Mice, Knockout | 2 | 2014 | 1692 | 0.040 |
Why?
|
| Leukocytes | 1 | 2018 | 99 | 0.040 |
Why?
|
| Adenoviridae | 1 | 2018 | 295 | 0.040 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2019 | 154 | 0.040 |
Why?
|
| Cell Culture Techniques | 1 | 2018 | 189 | 0.040 |
Why?
|
| Random Allocation | 1 | 2018 | 442 | 0.040 |
Why?
|
| Monocytes | 1 | 2018 | 210 | 0.040 |
Why?
|
| Mice, Inbred Strains | 2 | 2010 | 181 | 0.040 |
Why?
|
| Cord Blood Stem Cell Transplantation | 1 | 2016 | 21 | 0.030 |
Why?
|
| Fibrosis | 1 | 2018 | 371 | 0.030 |
Why?
|
| Coronary Vessels | 1 | 2018 | 313 | 0.030 |
Why?
|
| Esophagectomy | 1 | 2015 | 26 | 0.030 |
Why?
|
| Immunoblotting | 1 | 2015 | 254 | 0.030 |
Why?
|
| Carboplatin | 1 | 2015 | 59 | 0.030 |
Why?
|
| Mice, Nude | 1 | 2015 | 294 | 0.030 |
Why?
|
| Ventricular Remodeling | 1 | 2018 | 318 | 0.030 |
Why?
|
| Chemoradiotherapy | 1 | 2015 | 54 | 0.030 |
Why?
|
| Myofibroblasts | 1 | 2015 | 60 | 0.030 |
Why?
|
| Radiation, Ionizing | 1 | 2015 | 37 | 0.030 |
Why?
|
| Neoadjuvant Therapy | 1 | 2015 | 104 | 0.030 |
Why?
|
| Fluorouracil | 1 | 2015 | 130 | 0.030 |
Why?
|
| STAT3 Transcription Factor | 1 | 2015 | 86 | 0.030 |
Why?
|
| Paclitaxel | 1 | 2015 | 140 | 0.030 |
Why?
|
| Eukaryotic Initiation Factor-3 | 1 | 2014 | 5 | 0.030 |
Why?
|
| Cisplatin | 1 | 2015 | 192 | 0.030 |
Why?
|
| Thiazolidines | 1 | 2014 | 23 | 0.030 |
Why?
|
| DNA Damage | 1 | 2015 | 190 | 0.030 |
Why?
|
| Hepatocytes | 1 | 2015 | 205 | 0.030 |
Why?
|
| Protein Biosynthesis | 1 | 2014 | 181 | 0.030 |
Why?
|
| Biphenyl Compounds | 1 | 2014 | 184 | 0.030 |
Why?
|
| Heart | 1 | 2018 | 850 | 0.030 |
Why?
|
| In Vitro Techniques | 2 | 2006 | 765 | 0.030 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2013 | 24 | 0.030 |
Why?
|
| RNA Interference | 1 | 2014 | 266 | 0.030 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2013 | 30 | 0.030 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2013 | 18 | 0.030 |
Why?
|
| 3' Untranslated Regions | 1 | 2013 | 56 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2015 | 800 | 0.030 |
Why?
|
| Multigene Family | 1 | 2013 | 93 | 0.030 |
Why?
|
| Protein Interaction Mapping | 1 | 2013 | 62 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2013 | 132 | 0.030 |
Why?
|
| Survival Rate | 1 | 2015 | 1056 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2015 | 1046 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2013 | 306 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2014 | 331 | 0.020 |
Why?
|
| Homeostasis | 1 | 2013 | 291 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2013 | 567 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2015 | 1553 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2014 | 1200 | 0.020 |
Why?
|
| Megakaryocytes | 1 | 2010 | 18 | 0.020 |
Why?
|
| GATA1 Transcription Factor | 1 | 2010 | 19 | 0.020 |
Why?
|
| Platelet Activation | 1 | 2010 | 24 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2013 | 615 | 0.020 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2013 | 284 | 0.020 |
Why?
|
| Mutant Proteins | 1 | 2010 | 45 | 0.020 |
Why?
|
| Schwann Cells | 1 | 2010 | 33 | 0.020 |
Why?
|
| Platelet Count | 1 | 2010 | 100 | 0.020 |
Why?
|
| Gene Expression Regulation | 2 | 2006 | 1293 | 0.020 |
Why?
|
| Homozygote | 1 | 2010 | 119 | 0.020 |
Why?
|
| Mice, Mutant Strains | 1 | 2010 | 166 | 0.020 |
Why?
|
| Evoked Potentials, Auditory, Brain Stem | 1 | 2010 | 49 | 0.020 |
Why?
|
| Hair Cells, Auditory | 1 | 2010 | 60 | 0.020 |
Why?
|
| DNA Primers | 1 | 2010 | 302 | 0.020 |
Why?
|
| Heterozygote | 1 | 2010 | 174 | 0.020 |
Why?
|
| Prognosis | 1 | 2015 | 2093 | 0.020 |
Why?
|
| Recurrence | 1 | 2013 | 948 | 0.020 |
Why?
|
| Chromosomes, Human, Y | 1 | 2009 | 13 | 0.020 |
Why?
|
| Neuroglia | 1 | 2010 | 136 | 0.020 |
Why?
|
| Chromosomes, Human, X | 1 | 2009 | 24 | 0.020 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2009 | 37 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2010 | 322 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2011 | 312 | 0.020 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2009 | 29 | 0.020 |
Why?
|
| Perilipin-1 | 1 | 2009 | 6 | 0.020 |
Why?
|
| Fatty Acid-Binding Proteins | 1 | 2009 | 30 | 0.020 |
Why?
|
| Cochlea | 1 | 2010 | 169 | 0.020 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2009 | 63 | 0.020 |
Why?
|
| Antigens, Differentiation | 1 | 2009 | 49 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2009 | 144 | 0.020 |
Why?
|
| Muscle, Smooth | 1 | 2009 | 117 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2015 | 2358 | 0.020 |
Why?
|
| Thiazolidinediones | 1 | 2009 | 77 | 0.020 |
Why?
|
| Leptin | 1 | 2009 | 80 | 0.020 |
Why?
|
| Base Sequence | 1 | 2010 | 1015 | 0.020 |
Why?
|
| PPAR gamma | 1 | 2009 | 95 | 0.020 |
Why?
|
| Bone Marrow Transplantation | 1 | 2009 | 149 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2015 | 1070 | 0.020 |
Why?
|
| Phosphoproteins | 1 | 2009 | 202 | 0.020 |
Why?
|
| Growth Substances | 1 | 2006 | 77 | 0.020 |
Why?
|
| Discoidin Domain Receptors | 1 | 2006 | 16 | 0.020 |
Why?
|
| Receptors, Mitogen | 1 | 2006 | 23 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 2009 | 597 | 0.020 |
Why?
|
| Vimentin | 1 | 2006 | 47 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p19 | 1 | 2005 | 5 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2015 | 4848 | 0.020 |
Why?
|
| Diet | 1 | 2009 | 514 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2005 | 51 | 0.020 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2006 | 100 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2005 | 97 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2006 | 562 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2006 | 546 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2015 | 7029 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2005 | 682 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2002 | 30 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2002 | 32 | 0.010 |
Why?
|
| Antibodies | 1 | 2002 | 241 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2002 | 219 | 0.010 |
Why?
|